This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CYNO Cynosure (CYNO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Cynosure Stock (NASDAQ:CYNO) 30 days 90 days 365 days Advanced Chart Get Cynosure alerts:Sign Up Key Stats Today's Range$66.00▼$66.0050-Day Range N/A52-Week Range$39.90▼$66.65VolumeN/AAverage Volume1.24 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cynosure, Inc. develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women's health. The Company also markets radiofrequency (RF), energy-sourced medical devices for surgical applications, such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. The Company sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names. Its product portfolio includes single energy source systems, as well as workstations that incorporate two or more different types of lasers or light-based technologies. Read More Receive CYNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cynosure and its competitors with MarketBeat's FREE daily newsletter. Email Address CYNO Stock News HeadlinesAmerican Express Elects Randal K. Quarles and Noel Wallace to Board of DirectorsJuly 23, 2025 | tmcnet.comAfrican stories, films now global cynosure —Tolu AjayiJune 27, 2025 | msn.comAmerica’s Finest Hour: Sept 30After This White House Deadline, All Bets Are Off The White House just issued a sweeping order that could send U.S.-based AI stocks soaring. But there's a catch – this mandate comes with a strict September 30th deadline for federal agencies to comply. If you don't act before that, you could miss out on the biggest returns. One of Wall Street's most brilliant investment millionaires explains why in a new FREE video.August 16 at 2:00 AM | Stansberry Research (Ad)Authorities keep a keen eye on 'Silli tiger' in PTRJune 27, 2025 | msn.comSamantha Ruth Prabhu Dazzles In A Bodycon DressMay 27, 2025 | msn.comTesla's Retail Traders Get Buzzing As Board Reportedly Hunts For New CEO To Replace Elon MuskMay 1, 2025 | msn.comWhy the Eccles family, Dave Checketts are launching a $1.2B private-equity fundApril 30, 2025 | msn.comDave Checketts, Eccles Family Form $1.2B Private Equity Sports FundApril 22, 2025 | msn.comSee More Headlines CYNO Stock Analysis - Frequently Asked Questions How were Cynosure's earnings last quarter? Cynosure, Inc. (NASDAQ:CYNO) released its earnings results on Tuesday, July, 26th. The medical equipment provider reported $0.36 EPS for the quarter, beating the consensus estimate of $0.29 by $0.07. The business's quarterly revenue was up 31.8% compared to the same quarter last year. What other stocks do shareholders of Cynosure own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cynosure investors own include Global Blood Therapeutics (GBT), Hawkins (HWKN), DHT (DHT), NVIDIA (NVDA), Xtrackers California Municipal Bond ETF (CA), Golar LNG Partners (GMLP) and Micron Technology (MU). Company Calendar Last Earnings7/26/2016Today8/16/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:CYNO CIK885306 Webwww.cynosure.com Phone+1-978-2564200FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:CYNO) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredJPMorgan: Gold to $4,250—Here’s the Real PlayGold Surges And Some Investors Are Getting Paid, But Most Are Not. Which One Do You Want to Be? Gold prices ar...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cynosure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cynosure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.